Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | GRIK1 | P39086 | 12/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29758007 | 0.86 | KDM4E (0.53) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23466377 | 0.86 | KDM4E (0.53) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29183052 | 0.85 | GRIK1 (0.68) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9796166 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10740034 | 0.81 | ALDH1A1 (0.56) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29758108 | 0.80 | MEN1 (0.47) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23466628 | 0.80 | MEN1 (0.47) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1068813 | 0.79 | GAA (0.65) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31102464 | 0.79 | KDM4E (0.75) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6750019 | 0.79 | KDM4E (0.75) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420651-B2 | Substituted 1-alkylcinnolin-4(1H)-one derivatives, preparation thereof and therapeutic application of same | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-8410099-B2 | Substituted 1-benzyl-cinnolin-4(1H)-one derivatives, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2013-04-02 | — | — | US | disclosed |
| US-20120129864-A1 | SUBSTITUTED 1-ALKYLCINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION OF SAME | SANOFI (FR) | 2012-05-24 | — | — | US | disclosed |
| US-20110144115-A1 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129864-A1 | SUBSTITUTED 1-ALKYLCINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION OF SAME | ALK, CBR1, CBR3 | KDM4E 3133/4885ALDH1A1 718/4885MEN1 3928/4885 |
| US-20110144115-A1 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CNR1, CNR2, GPR18 | KDM4E 2334/4885ALDH1A1 2135/4885MEN1 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.